Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations (GOC-B-P)

Clinical Trial ID NCT01206049

PubWeight™ 3.14‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01206049

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
2 Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget 2015 1.02
3 Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol 2016 0.86
Next 100